RxDoctor Payments Data

Amy Lankford

Family · North Wilkesboro, NCNPI 1134776214

Payments from drug & device makers

$1,964in general payments, 2019–2025

Across 120 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$605
  • Forte Bio-pharma LLC$190
  • GSK$155
  • Novo Nordisk$139
  • USWM, LLC$123
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$82
  • plus $671 from 23 others

What the payments were for

  • Food & beverage$1,91497%
  • Education$503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,964 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,613
Medicare patients
60
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$101,930
BelbucaBuprenorphine Hcl73$70,342
Xtampza ErOxycodone Myristate98$63,836
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen350$58,046
MounjaroTirzepatide48$54,982
Nurtec OdtRimegepant Sulfate26$51,417
Hysingla ErHydrocodone Bitartrate35$23,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$22,785
TradjentaLinagliptin12$19,319
Tresiba Flextouch U-200Insulin Degludec16$18,273
JardianceEmpagliflozin13$18,193
Oxycodone Hcl665$15,448
LinzessLinaclotide15$15,257
MovantikNaloxegol Oxalate15$9,801
EucrisaCrisaborole12$9,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$18$134,177171 claims
Novo NordiskOzempic$139$101,93090 claims
PfizerNurtec Odt, Eucrisa$30$60,62638 claims
Lilly USA, LLCMounjaro$31$54,98248 claims
GSKTrelegy Ellipta, Breo Ellipta$155$31,52435 claims
AbbVieLinzess$605$15,25715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in North Wilkesboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →